FDA
-
-
-
-
-
-
-
Adamis Pharmaceuticals to Fund ZIMHI® Clinical Study with University of Leiden Opioid Expert
-
-
-
-
-
-
-
Adamis Pharmaceuticals Schedules First Quarter 2023 Financial Results Conference Call and Corporate Update
-
-
-
-
-
-
-
Adamis Pharmaceuticals (ADMP) Announce Nasdaq Grants Request for Extension to Comply with Continued Listing Requirements
-
-
-
-
-
-
-
Adamis Provides Update on the Phase 2/3 Trial of Tempol in COVID-19 Positive High-Risk Subjects
-
-
-
-
-
-
-
Adamis Pharmaceuticals (ADMP) Provides Update on Clinical Study Assessing Tempol for Treatment of COVID-19
-
-
-
-
-
-
-
Adamis Appoints Vickie Reed to Board of Directors
-
-
-
-
-
-
-
US WorldMeds and Adamis Pharmaceuticals Announce U.S. Launch of ZIMHI™ Naloxone Product
-
251,730 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All